[

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL

I									
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ess of Reporting Per		2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]							5. Relationship of Reporting Person(s) to Issue (Check all applicable)					
GAROFAL			3. Date of Earliest Transaction (Month/Day/Year)							Director Officer (give title	10% C Other	Owner (specify			
(Last)	(First)	(Middle)		06/02/2023							below)	below			
200 - 3650 GILMORE WAY					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)											X Form filed by One Reporting Person				
BURNABY	A1	V5G 4W8	3								Form filed by Mo Person	re than One Rep	porting		
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indicati					ation						
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	٦	Fable I - Nor	1-Deriva	tive S	ecurities Acq	uired,	Disp	osed of, o	or Ben	eficially	Owned				
1. Title of Security (Instr. 3) Date (Month/Date)					Execution Date,		tion nstr.	4. Securities Acquired (<i>I</i> Disposed Of (D) (Instr. 3 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														

<u> </u>															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		of Derivati Securiti Acquire (A) or Dispose of (D)	erivative ecurities cquired s) or isposed f (D) nstr. 3, 4		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$38.96	06/02/2023		A		18,475		(1)	06/01/2033	Common Shares	18,475	\$0	18,475	D	

Explanation of Responses:

1. Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

<u>/s/ Cassandra Robinson,</u> <u>Attorney-in-fact</u>	<u>06/02/2023</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.